Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Eli Lilly (NYSE:LLY) has agreed to acquire Boston-based gene editing startup Verve Therapeutics (NASDAQ:VERV) for up to $1.3B ...

Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now. On June 11, Eli Lilly announced a ...

Eli Lilly and Company (NYSE:LLY) may offer a modest dividend yield, but its track record of consistent payouts remains strong ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

(Reuters) -Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, aiming ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly and Company (NYSE: LLY) is reportedly in advanced talks to acquire gene editing biotech Verve Therapeutics Inc.

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

As part of the deal, Eli Lilly would pay almost $1bn upfront for Verve, which is developing a gene-editing therapy to treat bad cholesterol, and a further $300mn based on the biotech company achieving ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...